nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—ABCG2—Topotecan—cervical cancer	0.466	0.634	CbGbCtD
Ezetimibe—ABCB1—Topotecan—cervical cancer	0.168	0.229	CbGbCtD
Ezetimibe—CYP3A4—Topotecan—cervical cancer	0.101	0.137	CbGbCtD
Ezetimibe—SOAT1—exocrine gland—cervical cancer	0.0139	0.084	CbGeAlD
Ezetimibe—SOAT1—uterine cervix—cervical cancer	0.00599	0.0362	CbGeAlD
Ezetimibe—ANPEP—epithelium—cervical cancer	0.00578	0.0349	CbGeAlD
Ezetimibe—ANPEP—uterine cervix—cervical cancer	0.00573	0.0346	CbGeAlD
Ezetimibe—SOAT1—decidua—cervical cancer	0.00571	0.0345	CbGeAlD
Ezetimibe—SOAT1—renal system—cervical cancer	0.0056	0.0339	CbGeAlD
Ezetimibe—ANPEP—decidua—cervical cancer	0.00546	0.033	CbGeAlD
Ezetimibe—SOAT1—endometrium—cervical cancer	0.00542	0.0328	CbGeAlD
Ezetimibe—ANPEP—renal system—cervical cancer	0.00536	0.0324	CbGeAlD
Ezetimibe—SOAT1—mammalian vulva—cervical cancer	0.00524	0.0317	CbGeAlD
Ezetimibe—UGT2B15—female reproductive system—cervical cancer	0.00522	0.0316	CbGeAlD
Ezetimibe—ANPEP—endometrium—cervical cancer	0.00518	0.0313	CbGeAlD
Ezetimibe—ANPEP—mammalian vulva—cervical cancer	0.00501	0.0303	CbGeAlD
Ezetimibe—NPC1L1—Vitamin A and Carotenoid Metabolism—RARB—cervical cancer	0.005	0.141	CbGpPWpGaD
Ezetimibe—ANPEP—uterus—cervical cancer	0.00478	0.0289	CbGeAlD
Ezetimibe—SOAT1—female reproductive system—cervical cancer	0.00449	0.0271	CbGeAlD
Ezetimibe—ABCG5—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.0044	0.124	CbGpPWpGaD
Ezetimibe—ANPEP—female reproductive system—cervical cancer	0.00429	0.026	CbGeAlD
Ezetimibe—Interstitial lung disease—Topotecan—cervical cancer	0.00425	0.0662	CcSEcCtD
Ezetimibe—SOAT1—female gonad—cervical cancer	0.00408	0.0247	CbGeAlD
Ezetimibe—SOAT1—vagina—cervical cancer	0.00406	0.0245	CbGeAlD
Ezetimibe—UGT2B7—renal system—cervical cancer	0.00398	0.0241	CbGeAlD
Ezetimibe—ANPEP—C-MYB transcription factor network—PIAS3—cervical cancer	0.00392	0.111	CbGpPWpGaD
Ezetimibe—ANPEP—female gonad—cervical cancer	0.00391	0.0236	CbGeAlD
Ezetimibe—ANPEP—vagina—cervical cancer	0.00388	0.0235	CbGeAlD
Ezetimibe—ABCG8—Vitamin A and Carotenoid Metabolism—RARB—cervical cancer	0.00379	0.107	CbGpPWpGaD
Ezetimibe—ABCG5—Vitamin A and Carotenoid Metabolism—RARB—cervical cancer	0.00364	0.103	CbGpPWpGaD
Ezetimibe—UGT1A1—renal system—cervical cancer	0.00338	0.0205	CbGeAlD
Ezetimibe—UGT2B7—female reproductive system—cervical cancer	0.00319	0.0193	CbGeAlD
Ezetimibe—SLCO1B1—renal system—cervical cancer	0.00282	0.017	CbGeAlD
Ezetimibe—ABCC3—decidua—cervical cancer	0.00272	0.0165	CbGeAlD
Ezetimibe—ABCC3—renal system—cervical cancer	0.00267	0.0162	CbGeAlD
Ezetimibe—SOAT1—lymph node—cervical cancer	0.00263	0.0159	CbGeAlD
Ezetimibe—ANPEP—lymph node—cervical cancer	0.00251	0.0152	CbGeAlD
Ezetimibe—SLCO1B1—female reproductive system—cervical cancer	0.00226	0.0136	CbGeAlD
Ezetimibe—ABCC3—female reproductive system—cervical cancer	0.00214	0.0129	CbGeAlD
Ezetimibe—ABCC2—renal system—cervical cancer	0.00213	0.0129	CbGeAlD
Ezetimibe—Cramp muscle—Topotecan—cervical cancer	0.00196	0.0306	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00196	0.0306	CcSEcCtD
Ezetimibe—ABCC3—female gonad—cervical cancer	0.00195	0.0118	CbGeAlD
Ezetimibe—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00192	0.03	CcSEcCtD
Ezetimibe—ABCC2—female reproductive system—cervical cancer	0.00171	0.0103	CbGeAlD
Ezetimibe—Infestation—Topotecan—cervical cancer	0.00168	0.0262	CcSEcCtD
Ezetimibe—Infestation NOS—Topotecan—cervical cancer	0.00168	0.0262	CcSEcCtD
Ezetimibe—ABCG2—uterine cervix—cervical cancer	0.00166	0.0101	CbGeAlD
Ezetimibe—Neuropathy peripheral—Topotecan—cervical cancer	0.00165	0.0257	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Topotecan—cervical cancer	0.00159	0.0248	CcSEcCtD
Ezetimibe—ABCG2—decidua—cervical cancer	0.00159	0.00959	CbGeAlD
Ezetimibe—ABCG2—endometrium—cervical cancer	0.00151	0.0091	CbGeAlD
Ezetimibe—Pharyngitis—Topotecan—cervical cancer	0.0015	0.0233	CcSEcCtD
Ezetimibe—ABCG2—mammalian vulva—cervical cancer	0.00146	0.0088	CbGeAlD
Ezetimibe—ABCG2—uterus—cervical cancer	0.00139	0.00839	CbGeAlD
Ezetimibe—Angiopathy—Topotecan—cervical cancer	0.00137	0.0213	CcSEcCtD
Ezetimibe—Immune system disorder—Topotecan—cervical cancer	0.00136	0.0212	CcSEcCtD
Ezetimibe—Mediastinal disorder—Topotecan—cervical cancer	0.00136	0.0212	CcSEcCtD
Ezetimibe—Alopecia—Topotecan—cervical cancer	0.00133	0.0208	CcSEcCtD
Ezetimibe—Malnutrition—Topotecan—cervical cancer	0.00131	0.0205	CcSEcCtD
Ezetimibe—Back pain—Topotecan—cervical cancer	0.00127	0.0198	CcSEcCtD
Ezetimibe—Muscle spasms—Topotecan—cervical cancer	0.00126	0.0197	CcSEcCtD
Ezetimibe—ABCC3—lymph node—cervical cancer	0.00125	0.00757	CbGeAlD
Ezetimibe—ANPEP—Cardiac Progenitor Differentiation—NOTCH1—cervical cancer	0.00122	0.0345	CbGpPWpGaD
Ezetimibe—Ill-defined disorder—Topotecan—cervical cancer	0.00122	0.019	CcSEcCtD
Ezetimibe—Anaemia—Topotecan—cervical cancer	0.00121	0.0189	CcSEcCtD
Ezetimibe—Angioedema—Topotecan—cervical cancer	0.0012	0.0187	CcSEcCtD
Ezetimibe—Malaise—Topotecan—cervical cancer	0.00118	0.0185	CcSEcCtD
Ezetimibe—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.00117	0.0332	CbGpPWpGaD
Ezetimibe—Cough—Topotecan—cervical cancer	0.00115	0.0179	CcSEcCtD
Ezetimibe—ABCG2—female gonad—cervical cancer	0.00113	0.00686	CbGeAlD
Ezetimibe—ABCG2—vagina—cervical cancer	0.00113	0.00682	CbGeAlD
Ezetimibe—ANPEP—C-MYB transcription factor network—HES1—cervical cancer	0.00112	0.0316	CbGpPWpGaD
Ezetimibe—Chest pain—Topotecan—cervical cancer	0.00112	0.0174	CcSEcCtD
Ezetimibe—Myalgia—Topotecan—cervical cancer	0.00112	0.0174	CcSEcCtD
Ezetimibe—Arthralgia—Topotecan—cervical cancer	0.00112	0.0174	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00111	0.0173	CcSEcCtD
Ezetimibe—Discomfort—Topotecan—cervical cancer	0.00111	0.0172	CcSEcCtD
Ezetimibe—CYP3A4—renal system—cervical cancer	0.00108	0.00656	CbGeAlD
Ezetimibe—Anaphylactic shock—Topotecan—cervical cancer	0.00107	0.0167	CcSEcCtD
Ezetimibe—Infection—Topotecan—cervical cancer	0.00107	0.0166	CcSEcCtD
Ezetimibe—Nervous system disorder—Topotecan—cervical cancer	0.00105	0.0164	CcSEcCtD
Ezetimibe—Thrombocytopenia—Topotecan—cervical cancer	0.00105	0.0164	CcSEcCtD
Ezetimibe—Skin disorder—Topotecan—cervical cancer	0.00104	0.0162	CcSEcCtD
Ezetimibe—ABCC2—lymph node—cervical cancer	0.001	0.00605	CbGeAlD
Ezetimibe—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000977	0.0152	CcSEcCtD
Ezetimibe—Paraesthesia—Topotecan—cervical cancer	0.000963	0.015	CcSEcCtD
Ezetimibe—Dyspnoea—Topotecan—cervical cancer	0.000956	0.0149	CcSEcCtD
Ezetimibe—Dyspepsia—Topotecan—cervical cancer	0.000944	0.0147	CcSEcCtD
Ezetimibe—Decreased appetite—Topotecan—cervical cancer	0.000932	0.0145	CcSEcCtD
Ezetimibe—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000929	0.0263	CbGpPWpGaD
Ezetimibe—Gastrointestinal disorder—Topotecan—cervical cancer	0.000926	0.0144	CcSEcCtD
Ezetimibe—Fatigue—Topotecan—cervical cancer	0.000925	0.0144	CcSEcCtD
Ezetimibe—Constipation—Topotecan—cervical cancer	0.000917	0.0143	CcSEcCtD
Ezetimibe—Pain—Topotecan—cervical cancer	0.000917	0.0143	CcSEcCtD
Ezetimibe—Feeling abnormal—Topotecan—cervical cancer	0.000884	0.0138	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Topotecan—cervical cancer	0.000877	0.0137	CcSEcCtD
Ezetimibe—CYP3A4—female reproductive system—cervical cancer	0.000869	0.00525	CbGeAlD
Ezetimibe—Urticaria—Topotecan—cervical cancer	0.000852	0.0133	CcSEcCtD
Ezetimibe—Abdominal pain—Topotecan—cervical cancer	0.000848	0.0132	CcSEcCtD
Ezetimibe—Body temperature increased—Topotecan—cervical cancer	0.000848	0.0132	CcSEcCtD
Ezetimibe—ABCB1—epithelium—cervical cancer	0.000828	0.005	CbGeAlD
Ezetimibe—ABCB1—uterine cervix—cervical cancer	0.000821	0.00496	CbGeAlD
Ezetimibe—ABCC3—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000819	0.0232	CbGpPWpGaD
Ezetimibe—Hypersensitivity—Topotecan—cervical cancer	0.00079	0.0123	CcSEcCtD
Ezetimibe—ABCB1—decidua—cervical cancer	0.000782	0.00473	CbGeAlD
Ezetimibe—Asthenia—Topotecan—cervical cancer	0.000769	0.012	CcSEcCtD
Ezetimibe—ABCB1—renal system—cervical cancer	0.000768	0.00464	CbGeAlD
Ezetimibe—Pruritus—Topotecan—cervical cancer	0.000759	0.0118	CcSEcCtD
Ezetimibe—ABCB1—endometrium—cervical cancer	0.000742	0.00449	CbGeAlD
Ezetimibe—Diarrhoea—Topotecan—cervical cancer	0.000734	0.0114	CcSEcCtD
Ezetimibe—ABCG2—lymph node—cervical cancer	0.000729	0.00441	CbGeAlD
Ezetimibe—ABCB1—mammalian vulva—cervical cancer	0.000718	0.00434	CbGeAlD
Ezetimibe—Dizziness—Topotecan—cervical cancer	0.000709	0.0111	CcSEcCtD
Ezetimibe—ABCB1—uterus—cervical cancer	0.000684	0.00414	CbGeAlD
Ezetimibe—Vomiting—Topotecan—cervical cancer	0.000682	0.0106	CcSEcCtD
Ezetimibe—Rash—Topotecan—cervical cancer	0.000676	0.0105	CcSEcCtD
Ezetimibe—Dermatitis—Topotecan—cervical cancer	0.000676	0.0105	CcSEcCtD
Ezetimibe—Headache—Topotecan—cervical cancer	0.000672	0.0105	CcSEcCtD
Ezetimibe—Nausea—Topotecan—cervical cancer	0.000637	0.00993	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—CD4—cervical cancer	0.000632	0.0179	CbGpPWpGaD
Ezetimibe—ABCB1—female reproductive system—cervical cancer	0.000615	0.00372	CbGeAlD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.000588	0.0166	CbGpPWpGaD
Ezetimibe—ABCC3—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000573	0.0162	CbGpPWpGaD
Ezetimibe—ABCG2—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000565	0.016	CbGpPWpGaD
Ezetimibe—ABCB1—female gonad—cervical cancer	0.000559	0.00338	CbGeAlD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.000559	0.0158	CbGpPWpGaD
Ezetimibe—ABCB1—vagina—cervical cancer	0.000556	0.00336	CbGeAlD
Ezetimibe—ANPEP—Peptide hormone metabolism—CTNNB1—cervical cancer	0.000556	0.0157	CbGpPWpGaD
Ezetimibe—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000437	0.0124	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.000406	0.0115	CbGpPWpGaD
Ezetimibe—ABCG2—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000395	0.0112	CbGpPWpGaD
Ezetimibe—ABCB1—lymph node—cervical cancer	0.00036	0.00217	CbGeAlD
Ezetimibe—NPC1L1—Metabolism—CA9—cervical cancer	0.000331	0.00938	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.000302	0.00855	CbGpPWpGaD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000269	0.00761	CbGpPWpGaD
Ezetimibe—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000259	0.00733	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CA9—cervical cancer	0.000251	0.00711	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—CA9—cervical cancer	0.000242	0.00684	CbGpPWpGaD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.000234	0.00661	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000226	0.0064	CbGpPWpGaD
Ezetimibe—ABCC3—Fluoropyrimidine Activity—TP53—cervical cancer	0.000217	0.00615	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.000163	0.00461	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.000161	0.00456	CbGpPWpGaD
Ezetimibe—ABCG2—Fluoropyrimidine Activity—TP53—cervical cancer	0.00015	0.00424	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CA9—cervical cancer	0.000141	0.004	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—MTHFR—cervical cancer	0.000134	0.0038	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	0.000127	0.0036	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000122	0.00346	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.00011	0.00311	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—CTNNB1—cervical cancer	0.000105	0.00297	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—MTHFR—cervical cancer	0.000102	0.00288	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—MTHFR—cervical cancer	9.81e-05	0.00278	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CASP8—cervical cancer	8.31e-05	0.00235	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CA9—cervical cancer	7.58e-05	0.00214	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CA9—cervical cancer	6.44e-05	0.00182	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CA9—cervical cancer	6.44e-05	0.00182	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CASP3—cervical cancer	6.29e-05	0.00178	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—MTHFR—cervical cancer	5.74e-05	0.00162	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CA9—cervical cancer	5.24e-05	0.00148	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CA9—cervical cancer	4.8e-05	0.00136	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CA9—cervical cancer	4.44e-05	0.00126	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	4.1e-05	0.00116	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	3.1e-05	0.000878	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—MTHFR—cervical cancer	3.08e-05	0.00087	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	2.99e-05	0.000846	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—MTHFR—cervical cancer	2.61e-05	0.00074	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—MTHFR—cervical cancer	2.61e-05	0.00074	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CA9—cervical cancer	2.4e-05	0.000679	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	2.37e-05	0.00067	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—MTHFR—cervical cancer	2.12e-05	0.000601	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.99e-05	0.000563	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—MTHFR—cervical cancer	1.95e-05	0.000551	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—MTHFR—cervical cancer	1.8e-05	0.00051	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CA9—cervical cancer	1.48e-05	0.000419	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—MTHFR—cervical cancer	9.75e-06	0.000276	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—MTHFR—cervical cancer	6.01e-06	0.00017	CbGpPWpGaD
